Peking University First hospiatl
Beijing, 100000, China
NCT Number: NCT02609490
A phase 3 clinical study to evaluate the safety and efficacy of Azilsartan in Chinese hypertension patients
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 3
Beijing, 100000, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
14 patients with malignant tumors. 15. hemodialysis patients or strictly limit salt therapy. 16. Participated in other clinical trials within 30 days.
20mg/tablet
placebo tablet
20mg/tablet
placebo tablet
Time frame: 16 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 2 weeks
Time frame: 4 weeks
Time frame: 12weeks
Time frame: 2 weeks
Time frame: 4 weeks
Time frame: 12 weeks
Time frame: 16 week
do a 24-hour ambulatory blood pressure monitoring at baseline and at week 16, compare the decrease.
Lee's Pharmaceutical Limited
Industry
A Multi-center, Randomized, Double-blind, Double-dummy, With Olmesartan Medoxomil as Positive Control Parallel Clinical Study to Evaluate the the Safety and Efficacy of Azilsartan in Chinese Patients With Primary Mild and Moderate Hypertension
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05610059
Aging, Behavior
Tucson, Arizona, United States
View Trial DetailsNCT02439775
Cardiovascular Diseases, Hypertension
Huntsville, Alabama, United States
View Trial DetailsNCT07735468
Behavior, Cardiovascular Diseases
Osuna, Sevilla, Spain
View Trial DetailsNCT00837122
Cardiovascular Diseases, Diabetes
Accra, Ghana
View Trial Details